BR112014012155A2 - método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr - Google Patents

método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr

Info

Publication number
BR112014012155A2
BR112014012155A2 BR112014012155A BR112014012155A BR112014012155A2 BR 112014012155 A2 BR112014012155 A2 BR 112014012155A2 BR 112014012155 A BR112014012155 A BR 112014012155A BR 112014012155 A BR112014012155 A BR 112014012155A BR 112014012155 A2 BR112014012155 A2 BR 112014012155A2
Authority
BR
Brazil
Prior art keywords
egfr
resistant
cytotoxic agent
agent conjugate
treating tumors
Prior art date
Application number
BR112014012155A
Other languages
English (en)
Inventor
Setiady Julianto
U Park Peter
Chittenden Thomas
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of BR112014012155A2 publication Critical patent/BR112014012155A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo patente de invenção: "método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr". a presente invenção refere-se à identificação de que imunoconjugados de anticorpo egfr são eficazes na inibição do crescimento de células tumorais que desenvolveram mecanismos de resistência a egfr e/ou alk. métodos para administrar os imunoconjugados de anticorpo egfr aos pacientes tendo células tumorais resistentes são ainda divulgados.
BR112014012155A 2011-11-21 2012-11-21 método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr BR112014012155A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562157P 2011-11-21 2011-11-21
US201261639452P 2012-04-27 2012-04-27
PCT/US2012/066205 WO2013078271A1 (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Publications (1)

Publication Number Publication Date
BR112014012155A2 true BR112014012155A2 (pt) 2017-05-30

Family

ID=48470279

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012155A BR112014012155A2 (pt) 2011-11-21 2012-11-21 método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr

Country Status (16)

Country Link
US (1) US9233171B2 (pt)
EP (1) EP2794010A4 (pt)
JP (1) JP2014533954A (pt)
KR (1) KR20140105765A (pt)
CN (1) CN104066481A (pt)
AU (1) AU2012340686A1 (pt)
BR (1) BR112014012155A2 (pt)
CA (1) CA2856411A1 (pt)
CL (1) CL2014001282A1 (pt)
HK (1) HK1201772A1 (pt)
IL (1) IL232666A0 (pt)
MX (1) MX2014006087A (pt)
PH (1) PH12014501119A1 (pt)
RU (1) RU2014121820A (pt)
SG (1) SG11201402343SA (pt)
WO (1) WO2013078271A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013004761A (es) 2010-10-29 2013-08-27 Immunogen Inc Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
PT2668209T (pt) 2011-01-24 2021-04-07 Gilead Sciences Inc Anticorpos seletivos para células que apresentam egfr em alta densidade
EP2794010A4 (en) 2011-11-21 2015-10-21 Immunogen Inc METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
CA2915897A1 (en) * 2013-07-05 2015-01-08 Formation Biologics Inc. Egfr antibody conjugates
EP3044593A4 (en) * 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
US10273303B2 (en) 2013-11-13 2019-04-30 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
UA120607C2 (uk) * 2014-02-04 2020-01-10 Астеллас Фарма Інк. Фармацевтична композиція, яка включає діаміно-гетероциклічну карбоксамідну сполуку як активний інгредієнт
BR112016021717A2 (pt) * 2014-03-21 2018-07-10 Abbvie Inc anticorpos anti-egfr e conjugados anticorpo-fármaco
MA42561A (fr) 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
MA40968A (fr) * 2014-10-31 2017-10-04 Formation Biologics Inc Polythérapie à base d'anticorps anti-egfr
KR101692044B1 (ko) * 2014-12-05 2017-01-04 사회복지법인 삼성생명공익재단 교모세포종에서 표피 성장인자 수용체 억제제의 치료 효과를 예측하는 방법
US20180117053A1 (en) * 2015-05-27 2018-05-03 Metastat, Inc. The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
WO2017011618A1 (en) * 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of sirna and drug
SG11201910152XA (en) * 2017-03-31 2019-11-28 Univ Missouri Compositions for the treatment of drug-resistant tumors and methods of use thereof
CN107496933B (zh) * 2017-08-21 2019-12-24 山东新华制药股份有限公司 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法
KR20230106506A (ko) * 2022-01-03 2023-07-13 한국생명공학연구원 Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
SK281142B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
DK0699237T3 (da) 1994-03-17 2003-05-26 Merck Patent Gmbh Anti-EGFR enkeltkæde FV'er og anti-EGFR-antistoffer.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999022008A1 (fr) 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducteur pour la production d'un anticorps specifique de l'antigene, vecteur d'expression contenant le gene requis a cette fin, et procede pour induire la production de l'anticorps specifique de l'antigene
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
UA77157C2 (en) * 2000-02-25 2006-11-15 Polypeptide anti-egfrviii scfvs with improved cytotoxicity and output, molecule of nucleic acid, that codes the indicated polypeptide, and method of cell destructure with using of this polypeptide
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2002066058A1 (en) 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
DE602004031772D1 (de) 2003-12-04 2011-04-21 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
JP4901480B2 (ja) 2003-12-22 2012-03-21 グラクソ グループ リミテッド 神経疾患治療用の、ｎｏｇｏ−ａを中和する免疫グロブリン
EP1735348B1 (en) 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
ES2741574T3 (es) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
CN102603770A (zh) 2005-04-15 2012-07-25 免疫基因公司 消除肿瘤中的异质或混合细胞群体
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
BRPI0715917A2 (pt) 2006-08-11 2014-11-25 Schering Corp Anticorpos para il-17a
US20090258442A1 (en) 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
WO2008098145A1 (en) 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
DK2132229T3 (en) 2007-03-01 2016-06-20 Symphogen As Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
US7892777B2 (en) 2007-07-17 2011-02-22 The Regents Of The University Of Michigan Methods for measuring whether a treatment affects RPTP-κ activity
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
SI2281006T1 (sl) 2008-04-30 2017-12-29 Immunogen, Inc. Premreževalci in njihova uporaba
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
CN102159248B (zh) 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
CA2740098A1 (en) 2008-10-10 2010-04-15 Valerie Odegard Tcr complex immunotherapeutics
US20110287036A1 (en) 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
CN103003424B (zh) 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
MX2013004761A (es) 2010-10-29 2013-08-27 Immunogen Inc Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
EP2794010A4 (en) 2011-11-21 2015-10-21 Immunogen Inc METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE

Also Published As

Publication number Publication date
CN104066481A (zh) 2014-09-24
CA2856411A1 (en) 2013-05-30
CL2014001282A1 (es) 2014-11-14
RU2014121820A (ru) 2015-12-27
SG11201402343SA (en) 2014-06-27
US20130156796A1 (en) 2013-06-20
EP2794010A1 (en) 2014-10-29
US9233171B2 (en) 2016-01-12
IL232666A0 (en) 2014-07-31
AU2012340686A1 (en) 2014-06-19
MX2014006087A (es) 2014-08-01
HK1201772A1 (en) 2015-09-11
KR20140105765A (ko) 2014-09-02
EP2794010A4 (en) 2015-10-21
PH12014501119A1 (en) 2014-08-04
JP2014533954A (ja) 2014-12-18
WO2013078271A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
BR112014012155A2 (pt) método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr
BR112018075198A2 (pt) método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112017023233A2 (pt) métodos para tratamento de câncer
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112014016163A2 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BR112016012410A2 (pt) conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
BR112022000231A2 (pt) Novos métodos
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]